U.S. Large And Small-scale Bioprocessing Market

U.S. Large And Small-scale Bioprocessing Market Summary

The U.S. large and small-scale bioprocessing market size was estimated at USD 24.86 billion in 2024 and is projected to reach USD 67.34 billion by 2033, growing at a CAGR of 11.24% from 2025 to 2033. This growth is driven by the rising global demand for biologics, including monoclonal antibodies, vaccines, and cell and gene therapies.

Biopharmaceutical companies are increasingly investing in flexible manufacturing solutions, such as single-use technologies and modular bioprocessing systems, to accelerate development timelines and reduce costs.

Growing Adoption of Single-Use Technologies in U.S. Bioprocessing

The increasing implementation of single-use technology (SUT) is transforming the U.S. large- and small-scale bioprocessing market, enabling greater flexibility, operational efficiency, and cost-effectiveness in biologics manufacturing. Single-use systems, including bioreactors, bags, filters, connectors, and tubing, are increasingly favored over traditional stainless-steel setups, particularly for small-batch and multiproduct facilities. Their ability to reduce cleaning validation, lower the risk of cross-contamination, and minimize turnaround times makes them highly suitable for modern, fast-paced bioproduction environments. As the demand for personalized medicine and modular manufacturing grows, SUT adoption is accelerating across both clinical and commercial stages.

Biopharmaceutical companies and CDMOs are leveraging single-use technologies to streamline scale-up processes, shorten development timelines, and meet the increasing need for agile production. These systems are particularly valuable in early-stage manufacturing, where flexibility and speed are critical. The growth of cell and gene therapies, which often require small, high-value batches, is further driving the shift toward SUT-based infrastructure. Additionally, the rise of multiproduct facilities demands rapid changeovers, which are more efficiently supported by single-use components than traditional clean-in-place systems.

Manufacturers of bioprocessing equipment are continuously innovating within the SUT space to enhance performance, durability, and compatibility with complex biologics. Developments such as gamma-stable polymers, automation-integrated systems, and scalable single-use platforms are expanding the applicability of SUTs beyond early-stage production to include commercial-scale operations. Key industry players are also investing in hybrid bioprocessing models, combining single-use and stainless-steel systems, to balance cost, scale, and compliance. This trend reflects the evolving needs of manufacturers to customize production environments based on batch size, product type, and regulatory requirements.

Looking ahead, the growth trajectory of SUT in the U.S. bioprocessing market is supported by strong regulatory acceptance, increasing investment in flexible manufacturing facilities, and the expanding pipeline of biologics and advanced therapies. The technology’s ability to reduce capital expenditure, operational risk, and production downtime positions it as a core enabler of next-generation biomanufacturing. As the industry continues to prioritize speed, safety, and scalability, single-use systems are expected to play an even more central role in shaping the future of bioprocessing in the U.S.

U.S. Large And Small-Scale Bioprocessing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. large and small-scale bioprocessing market based on scale, workflow, product, application, use-type, and mode:

• Scale Outlook (Revenue, USD Million, 2021 - 2033)
• Industrial Scale (Over 50,000 Liter)
• Small Scale (Less Than 50,000 Liter)
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Downstream Processing
• Fermentation
• Upstream Processing
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Bioreactors/Fermenters
• Cell Culture Products
• Filtration Assemblies
• Bioreactors Accessories
• Bags & Containers
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceuticals
• Speciality Industrial Chemicals
• Environmental Aids
• Use-Type Outlook (Revenue, USD Million, 2021 - 2033)
• Multi-Use
• Single-Use
• Mode Outlook (Revenue, USD Million, 2021 - 2033)
• In-House
• Outsourced

Please note The report will be delivered in 2-3 business days upon order notification. Show more